Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Conference organizers must adopt a novel, comprehensive approach to ensure increased accessibility, diversity and inclusivity of post-pandemic conferences.
Race to the clinic reignites for an off-the-shelf alternative to autologous CAR-T cell therapy, even as concerns over chromosomal abnormalities linger.
Sanatech Seed’s Sicilian Rouge CRISPR-edited ‘health-promoting’ tomatoes reach consumers and may open the market to more genome-edited fruit, vegetables and even fish.
Peptide jabs targeting T cells could be especially useful for people with compromised immune systems, as backups for spike-based vaccines, or against Omicron and other emerging variants.
Eighteen years after its inception, the international Genetically Engineered Machine competition has catalyzed the infusion of synthetic biology with interdisciplinary fundamental and translational research, as well as with inspired young scientists.
As pharmaceutical companies seek patent protection for combinations of cancer therapeutics, it is worthwhile to assess what constitutes an ‘unexpected result’ for the purpose of an appropriate patent and whether randomized, controlled trials of drug combinations have the ability to generate them.